(Q33794087)

29 July 2017

1 reference

title

Efficacy of viral clearance methods used in the manufacture of activated prothrombin complex concentrates: focus on AUTOPLEX T. (English)

1 reference

29 July 2017

Horwith G

1

1 reference

29 July 2017

Revie DR

series ordinal

2

1 reference

29 July 2017

language of work or name

1 reference

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

5 Suppl 3

1 reference

29 July 2017

page(s)

19-23

1 reference

Is the apparent outbreak of hepatitis A in Belgian hemophiliacs due to a loss of previous passive immunity?

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Outbreak of hepatitis A among Italian patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Inactivation of hepatitis A virus in plasma products by vapor heating

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Viral safety of a new highly purified factor VIII (OCTATE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Eliminating parvovirus B19 from blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Estimated risk of transmission of hepatitis C virus by blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Lack of seroconversion for LAV/HTLV-III in patients exclusively given unheated activated prothrombin complex prepared with ethanol step

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

Inactivation of HTLV-III/LAV during plasma fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00033.X

10.1046/J.1365-2516.1999.00033.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference